EQRx, Inc. (EQRX)の価格はいくらですか

EQRx, Inc. (EQRX)の価格は$2.34です

EQRx, Inc. (EQRX)の時価総額は何ですか

EQRx, Inc. (EQRX)の時価総額は$728.90Mです

EQRx, Inc. (EQRX) の利益

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

年	利益	変化
提供された日付のデータは十分ではありません。

年

利益

変化

提供された日付のデータは十分ではありません。

企業	利益	利益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

企業

利益

利益の差

国

Vertex Pharmaceuticals Incorporated

VRTX.US

$5.27B

Argenx SE

ARGX.US

$1.95B

CSL Limited

CSL.AX

$-4.02B

Moderna, Inc.

MRNA.US

$-3.09B

Lonza Group AG

LONN.SW

EQRx, Inc.

EQRX

カテゴリー